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E-mail: dkohn1@mednet.ucla.eduAdenosine deaminase (ADA)-deficient mice and healthy rhesus
monkeys were studied to determine the impact of age at treat-
ment, vector dosage, dosing schedule, repeat administration,
biodistribution, and immunogenicity after systemic delivery
of lentiviral vectors (LVs). In Ada/mice, neonatal treatment
resulted in broad vector marking across all tissues analyzed,
whereas adult treatment resulted in marking restricted to the
liver, spleen, and bone marrow. Intravenous administration
to infant rhesus monkeys also resulted in dose-dependent
marking in the liver, spleen, and bone marrow. Using an ELISA
to monitor anti-vector antibody development, Ada/
neonatal mice did not produce an antibody response, whereas
Ada/ adult mice produced a strong antibody response to
vector administration. In mice and monkeys with repeat
administration of LV, a strong anti-vector antibody response
was shown in response to the second LV administration, which
resulted in LV inactivation. Three separate doses administered
to immune competent mice resulted in acute toxicity. Pegyla-
tion of the vesicular stomatitis virus G protein (VSV-G)-envel-
oped LVs showed a less robust anti-vector response but did not
prevent the inactivation of the second LV administration.
These studies identify important factors to consider related
to age and timing of administration when implementing sys-
temic delivery of LVs as a potential therapeutic agent.
INTRODUCTION
Lentiviral vectors (LVs) have been described as an efficient delivery
vehicle suitable for direct injection and gene delivery in vivo, owing
mostly to the ability to achieve gene transfer in non-dividing cells.1
Since these initial studies, systemic delivery of LVs has been
considered for a number of monogenic diseases, including the
coagulation deficiencies hemophilia A2 and hemophilia B,3 inborn
errors of metabolism such as lysosomal storage disorders MPS1,4
MPS3a,5 MPS3b,6 bilirubin-UDP-glucuronosyltransferase defi-78 Molecular Therapy: Methods & Clinical Development Vol. 16 March
This is an open access article under the CC BY license (http://creativciency (Crigler-Najjar),7 Pompe disease,8 and adenosine deaminase
(ADA) deficiency,9 among others. In many instances, systemic de-
livery of LVs was first investigated as a neonatal approach in mu-
rine and other animal models to prevent or ameliorate disease
pathology.10
ADA deficiency is an inborn error of metabolism that results in the
accumulation of adenosine and deoxyadenosine metabolites resulting
from absent or aberrant Ada gene expression. Patients are most
notably stricken with severe combined immunodeficiency (SCID),
as normal lymphocyte development is severely impaired by the accu-
mulation of these metabolites.11 Infants typically present with severe
and persistent infections characterized by a failure-to-thrive and
profound lymphopenia. In addition to SCID, affected ADA-deficient
individuals may also have hepatic, renal, pulmonary, skeletal, and/or
neurological pathology associated with the accumulation of
metabolites.12
ADA-deficient patients with a matched sibling donor can be treated
soon after diagnosis with hematopoietic stem cell transplantation
(HSCT). If no suitable donor is available, a patient may be stabilized
with enzyme replacement therapy (ERT) bovine ADA conjugated to
polyethylene glycol (PEG-ADA) (ADA-GEN, Leadiant Biotechnol-
ogies, Gaithersburg, MD, USA). ERT can substantially increase
lymphocyte counts and provide some immune reconstitution; long-
term use, however, has been associated with waning immune cell
numbers and function.13 More recently, ERT has been accepted as2020 ª 2019 The Authors.
ecommons.org/licenses/by/4.0/).
Figure 1. Survival, Biodistribution, and
Immunogenicity in Ada–/– Mice
(A) Schematic of vector administration and analysis (ar-
row) timeline. Controls not depicted. (B) Kaplan-Meier
survival curves. (C) Biodistribution and quantitation of
vector sequences (VCNs) in tissue. Lines represent
the median VCN in each tissue: Neonate (n = 16), Adult
1 (N = 15), and Adult 2 (n = 5). (D) Mean (±SEM)
concentration of anti-vector antibody in plasma (mg/mL):
ERT (n = 5), Neonate (N = 7), Adult 1 (N = 12), Adult 2
(n = 5). (E) Mean (±SEM) VCN measured in liver (light bar)
and spleen (dark bar): ERT (n = 5), Neonate (n = 7), Adult
1 (n = 12), Adult 2 (n = 5).
www.moleculartherapy.organ important bridge to a more durable HSC treatment.14 In recent
clinical trials, many patients have been successfully treated with autol-
ogous HSCs ex vivo gene therapy using retroviral (gamma and lenti-
viral) gene-corrected CD34+ hematopoietic stem and progenitor cells
(HSCT GT).15
For patients where a stem cell therapy may not be an option,
including older patients with ADA deficiency with partial ADA
expression associated with late/adult onset, enzyme replacement by
in vivo Ada gene delivery could provide an alternative therapeutic
approach. In prior studies, we reported that a single injection of
ADA-expressing LVs could rescue ADA-deficient (Ada/) neonatal
mice, which would typically succumb to adenosine and deoxyadeno-
sine accumulation in the lungs by postnatal day 21 (3 weeks).9 How-
ever, it seems unlikely that most patients with late onset ADA-defi-Molecular Therapy: Methods &ciency will be identified and treated within the
neonatal period. Thus, further studies in animal
models beyond the neonatal period are essential
for understanding the effect of age on treatment
outcome, as well as the dosing schedule
(including repeat administration), and the po-
tential to elicit an immune response. In these
studies, we used the ADA-deficient mouse
model and healthy young rhesus monkeys to
address these questions. Importantly, the find-
ings described herein provide valuable insights
for preclinical studies that include systemic
administration of LVs for the treatment of other
monogenic diseases.
RESULTS
Dosing Schedule and Biodistribution in
Ada–/– Mice
In previous studies, Ada/ mice were rescued
in a dose-dependent manner by systemic intra-
venous administration of a lentiviral vector
(LV)-expressing human ADA, surviving past
3 weeks without further treatment.9 Ada/
neonates treated with 5.0  10e9 TU/kg
(1.0  10e7 TU/neonate) did not survivepast day 30, while those treated with a 10-fold higher dose of
5.0  10e10 TU/kg (1.0  10e8 TU/neonate) survived with good
immune reconstitution and resolution of the lethal pulmonary
insufficiency.9 In another related study, biodistribution analyses
demonstrated differences in the amount of LVs detected in
Ada/ mice treated as newborns (at birth) compared to healthy in-
fant rhesus monkeys treated at 1 month of age where no vector was
detected in the rhesus thymus or brain.16 However, it was not clear
whether the differences observed were species-specific, develop-
mental age-specific, or disease-specific.
In these studies, neonatalAda/ and adultAda/mice were treated
with an intravenous injection of LV expressing the human Ada gene
(ADA LV) to assess the effects of age on survival and LV bio-
distribution (Figure 1A; Figure S1). Litters of Ada/ and Ada+/Clinical Development Vol. 16 March 2020 79
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5.0 10e10 TU/kg of ADA LV (“Neonate groups”). Some litters were
treated with supplemental polyethylene glycol (PEG)-ADA ERT for
the first month post treatment (Neonate ERT) and others received
no supplemental ERT post-treatment (Neonate No ERT) (Table 1).
Ada/ mice treated at 4 months of age comprised the Adult groups
and either received a single dose of 1.5-3  10e10/kg (Adult 1) or
two doses of 1.5–10e10/kg within 3 days (Adult 2). The Adult group
were administered PEG-ADA ERT from birth until the time of LV
treatment at 4 months of age and then for 1 month post-LV
treatment.
Survival of Ada/ mice in the Neonate group with ERT was 70.6%.
When compared to untreated Ada/ mice, the probability of sur-
vival was higher (p = 0.0493) (Figure 1B). Survival of Ada/ mice
in the Neonate group without ERT was 46.2% and was
not significantly different when compared to untreated Ada/
mice (p = 0.8802). Survival of Ada/ mice in the Adult group
was 100% when administered a single dose and was 83.3% when
treated with two doses. Compared to untreated Ada/ mice, the
probability of survival was significantly higher in Ada/ Adult
mice with a single dose (Adult 1; p = 0.0001) or two doses (Adult
2; p = 0.0016).
As observed in our prior studies,9,16 Ada/ mice in the Neonate
group, treated with a single ADA LV administration, showed the
highest vector copy number (VCN) in liver (0.337 ± 0.241 copies/
cell) (Figure 1C). Similarly, marking was also highest in liver when
mice were treated as Adults once (Adult 1, 0.039 ± 0.0187 copies/
cell) or twice within 3 days (Adult 2, 0.026 ± 0.0114 copies/cell).
In the Adult group treated once, results in tissue VCN were
significantly lower (10- to 1,000-fold) in thymus (p < 0.0001), liver
(p = 0.002), lung (p < 0.0001), heart (p < 0.0001), adrenal glands
(p < 0.0001), kidneys (p < 0.0001), and brain (p < 0.0001) compared
to the Neonate group. Similar results were observed in the Adult
group treated twice compared to those in the Neonate group treated
once, with tissue VCN significantly lower in thymus (p = 0.004),
spleen (p = 0.003), liver (p = 0.005), lung (p = 0.003), heart
(p = 0.003), adrenal glands (p = 0.002), kidneys (p = 0.001), and brain
(p = 0.001). The only tissue not significantly different was
bone marrow in mice in the Adult group treated once or twice
(p = 0.165). Due to vector concentration and delivery volume con-
straints, mice in the Adult group received approximately one-third
(Adult 1) to one-half (Adult 2) the neonatal dose, which could
explain the decreased marking in these tissues; however, in many tis-
sues the difference in marking far exceeded the difference in dose by
10- to 1,000-fold.
In previous studies, we reported that Ada/ mice surviving beyond
3 weeks after treatment with intravenous LV without supplemental
ERT had sufficient ADA enzyme activity to reconstitute the lympho-
cyte compartment.9,17 Likewise, in this study there were no differ-
ences across the treatment modalities in lymphocyte cell percentages
or absolute numbers (Figure S2).80 Molecular Therapy: Methods & Clinical Development Vol. 16 MarchAnti-Vector Responses in Ada–/– Mice
To determine the potential for producing anti-vector antibodies and
inactivating subsequent administration of vesicular stomatitis virus G
protein (VSV-G)-pseudotyped LV, we developed an ELISA using
concentrated stocks of LV as the capture antigen for the detection
of anti-vector antibodies (immunoglobulin G, IgG) in the plasma of
treated mice.18 The relative concentration of anti-vector antibodies
was quantified by comparing the anti-vector IgG concentration in
the sample to the signal detected in the standard curve of serially
diluted primary mouse anti-VSV-G IgG.
To determine whether Ada/ mice treated with systemic ADA LV
could mount an adaptive immune response to initial and subsequent
vector administration, we measured the concentrations of anti-vector
antibodies in plasma samples at the time of analysis (Figure 1D). In
Ada/ mice in the Neonate group, the mean (±SEM) anti-vector
IgG concentration at 8 months post treatment was slightly above
background (29 ± 18 mg/mL) and not significantly different than
Ada/ mice treated only with ERT (p = 0.1931) (Figure 1D). In
contrast, in Ada/ mice treated in the Adult group, the anti-vector
concentration at 4 months post treatment was 200-fold higher
(6,842 ± 1,653 mg/mL) after one vector dose (p = 0.0002) and over
500-fold higher (17,612 ± 1,089 mg/mL) after two doses given 3 days
apart (p = 0.0055) when compared to Ada/ mice in the Neonate
group. Interestingly, Ada/ mice in the Adult group treated twice
within 3 days had a significantly stronger response compared to
those treated once (p = 0.0111) without significant changes in liver
(p = 0.430) or spleen (p = 0.0760) VCN (Figure 1E). A time course
performed on treated Ada/ mice in the Adult group revealed that
a strong anti-vector response developed within the first month after
treatment and was stable from month 1 to month 4 post treatment
(Table 2).
Anti-vector Response to PEG-Modified LVs and Repeat
Administration in Ada+/– Mice
We investigated the use of LVs modified with conjugated PEG to
reduce the potential for vector inactivation as previously reported.19
PEG molecules were conjugated to lysine residues within the
VSV-G at the diafiltration step during vector concentration.20
To control for the pegylation process, we split one batch of partially
concentrated enhanced GFP (eGFP) LV (27.5-fold) into two frac-
tions, where one fraction underwent the pegylation process and the
other fraction remained unmodified (Table S1). The PEG-eGFP LV
titer was 8.8  10e8 TU/mL and the unmodified eGFP LV titer was
6.6  10e8 TU/mL, indicating pegylation did not diminish the viral
titer. Using direct competitive ELISA, the PEG molecules conjugated
to each LV was quantified. The unmodified eGFP LV had no detect-
able PEG, whereas the PEG-eGFP LV had 275,000 ng/mL of PEG.
To delineate the role of the adaptive immune response in the persis-
tence of liver marking in immune-competent mice, we compared
Ada+/ littermates treated with LV as Neonates in the same manner
as their Ada/ littermates. Additionally, older Ada+/ mice were2020
Table 1. Viral Vector, Titer, and Dose in Mouse and Rhesus Monkey Studies
Vector Used in Studies Short Name
Transgene
Expressed Titer (TU/mL) Dose (TU/kg) Age of Treatment PEG Modified
Mouse Studies (Figures 1, 2, and 3)
HIV-MNDU3-ADA/VSV (MND-ADA-LV) yes 8.0  10e9 5.0  10e10 birth no
HIV-EFS-ADA/VSV (EFS-ADA-LV) yes 7.0  10e9 2.5  10e10 birth no
HIV-UCOE-EFS-ADA/VSV
(UCOE-EFS-ADA-
LV)
yes 1.0 x10e10 2.5-5.0  10e10 birth no
HIV-MNDU3-ADA/VSV (MND-ADA-LV) yes 8.0  10e9 1.5  10e10 4–5 months no
HIV-EFS-ADA/VSV (EFS-ADA-LV) yes 7.0  10e9 1.5  10e10 4–5 months no
HIV-UCOE-EFS-ADA/VSV
(UCOE-EFS-ADA-
LV)
yes 1.0  10e10 1.5  10e10 4–5 months no
HIV-MNDU3-eGFP/VSV (eGFP-LV) yes 8.8  10e8 1.7  10e8 4–5 months no
HIV-MNDU3-eGFP/VSV-
PEG
(PEG-eGFP-LV) yes 6.6  10e8 1.7  10e8 4–5 months yes
Rhesus Monkey Study 1 and 2 (Figure 4)
SIV-MNDU3-ADA/VSV (SIV-ADA-LV) yes 3.6  10e9 1.0  10e10 birth no
SIV-MNDU3-ADA/VSV (SIV-ADA-LV) yes 2.0  10e10 1.0  10e11 birth no
SIV-MNDU3-ADA/VSV (SIV-ADA-LV) yes 3.7  10e10 3.7  10e9 4 months no
SIV-MNDU3-ADA/VSV (SIV-ADA-LV) yes 3.7  10e10 3.7  10e10 4 months no
Rhesus Monkey Study 3 (Figures 5 and Table S3)
SIV-FXM10/VSV (FX-LV) no 2.0  10e10 2.0  10e9 1 month no
SIV-NeoNT/VSV (NeoNT-LV) no 1.0  10e10 2.0  10e9 4 months no
Rhesus Monkey Study 4 (Figures 6 and Table S3)
SIV-FXM10/VSV (FX-LV) no 2.9  10e9 2.0  10e9 3 months no
SIV-NeoNT/VSV (NeoNT-LV) no 1.6  10e10 2.0  10e9 6 months no
SIV-NeoNT/VSV-PEG (PEG-NeoNT-LV) no 9.6  10e9 2.0  10e9 6 months yes
VSV, vesicular stomatitis virus glycoprotein; HIV-1, human immunodeficiency virus 1; SIV, simian immunodeficiency virus; FX, Phi X-174 bacteriophage DNA; NeoNT, non-ex-
pressed neomycin resistance gene; PEG, polyethylene glycol; TU, transducing units.
www.moleculartherapy.orgtreated as Adults once at 5 months of age (Figure 2A). Ada+/ mice
are phenotypically normal and do not succumb if no treatment is
given. All Ada+/ mice treated as Neonates or Adults with unmodi-
fied LV or PEG-modified LV survived after treatment (Figure 2B).
Immune-competent Ada+/ mice treated once as Neonates with the
ADA LV had similar mean liver VCN (0.128 ± 0.066 copies) and
anti-vector IgG concentration (275 ± 193 mg/mL) when compared
to the mean liver VCN (0.084 ± 0.056 copies; p = 0.5912) and
anti-vector IgG concentration (1,137 ± 2.5 mg/mL; p = 0.1065) in
Ada+/ mice treated once with the ADA LV as Adults at 5 months
(Figures 2C and 2D). Ada+/ mice treated as Adults with the eGFP
LV received a lower dose due to low titer and volume constraints,
compared to those Ada+/ mice treated as Neonates with the ADA
LV. However, despite the higher dose, those Ada+/ mice treated as
Neonates with ADA LV had significantly lower anti-vector IgG con-
centration compared to Ada+/ mice treated as Adults at 5 months
with the eGFP LV (p = 0.0084), PEG-eGFP LV (p = 0.0029), PEG-
eGFP LV twice within 3 days (p = 0.0221), or PEG-eGFP LV twice
at 5 and 8 months of age (p = 0.0141) (Figure 2C). In contrast, there
were no significant differences in either the anti-vector IgG concen-Molecultration or liver VCN in Ada+/mice treated at 5 months with a single
administration of the ADA LV, the unmodified eGFP LV, or the PEG-
eGFP LV, suggesting no increased immunogenicity of the eGFP LVs.
Only those Ada+/ mice treated with the PEG-eGFP LV at 5 and
8 months had a significantly higher anti-vector IgG concentration
compared to those treated once with the eGFP LV (p = 0.0369) or
the PEG-eGFP LV (p = 0.0222). Additionally, the mean VCN at the
time of analysis was 10- to 100-fold lower in mice treated with the
PEG-eGFP LV twice at 5 and 8 months compared with those mice
treated at 5 months once with the PEG-eGFP LV (p = 0.0518) or twice
within 3 days with the PEG-eGFP LV (p = 0.0722); however, these dif-
ferences were not statistically significant. Taken together, these results
suggest that pegylation of the eGFP LV did not provide protection
against an anti-vector response.
To study the potential for LV inactivation, we treatedmice at different
time points with two different vectors each carrying distinct trans-
genes, allowing for detection of each vector (Figure 3A). As seen in
the previous study with the same type of vector, administration of
two different LVs was well tolerated, with all mice surviving to the
end of the study (Figure 3B). The anti-vector IgGmean concentrationar Therapy: Methods & Clinical Development Vol. 16 March 2020 81
Table 2. Anti-Vector IgG Concentration at 1, 2, and 4 Months after Treatment of Mice with a Single Dose of LV
Genotype LV Treatment Age of Treatment Dose
Anti-Vector Antibody after Treatment (mg/mL)
Mouse ID 1 Month 2 Months 4 Months
1573 Ada+/ eGFP adult 1.65  10e8/kg 144 144 144
1583 Ada+/ eGFP adult 1.65  10e8/kg 674 680 658
1586 Ada+/ eGFP adult 1.65  10e8/kg 2,440 2,340 2,380
1572 Ada+/ PEG-eGFP adult 1.65  10e8/kg 2,380 2,380 2,300
1579 Ada+/ PEG-eGFP adult 1.65  10e8/kg 690 686 676
1585 Ada+/ PEG-eGFP adult 1.65  10e8/kg 6,740 6,820 6,760
1588 Ada+/ PEG-eGFP adult 1.65  10e8/kg 2,320 2,360 2,360
1543 Ada/ EFS-ADA adult 3.0  10e10/kg 1,760 1,792 1,766
1548 Ada/ EFS-ADA adult 3.0  10e10/kg 1,808 1,888 1,826
1552 Ada/ EFS-ADA adult 3.0  10e10/kg 1,360 1,340 1,320
1549 Ada/ MND-ADA adult 3.0  10e10/kg 2,560 2,540 2,560
1555 Ada/ MND-ADA adult 3.0  10e10/kg N/A 158 138
1556 Ada/ MND-ADA adult 3.0  10e10/kg 1,876 1,868 1,836
1569 Ada/ MND-ADA adult 3.0  10e10/kg 17,700 17,360 17,660
1544 Ada/ UCOE-EFS-ADA adult 3.0  10e10/kg 1,776 1,828 1,880
1554 Ada/ UCOE-EFS-ADA adult 3.0  10e10/kg 2,560 2,556 2,570
1571 Ada/ UCOE-EFS-ADA adult 3.0  10e10/kg 1,900 1,818 1,836
1576 Ada/ UCOE-EFS-ADA adult 3.0  10e10/kg 2,576 2,551 2,555
ID, Identification; LV, lentiviral vector; N/A, not available.
Molecular Therapy: Methods & Clinical Developmentafter Ada+/ mice treated as Neonates (0 months) with the ADA LV
and at 8 months with the eGFP LV was not different when compared
to mice treated with the ADA LV at birth and the PEG-eGFP LV at
8 months (Figure 3C). When Adult mice were initially treated with
the unmodified eGFP LV at 5 months, followed by the ADA LV
at 8 months, the mean anti-vector IgG concentration was increased
11-fold (114,667 ± 667 mg/mL) compared to mice first treated with
the PEG-eGFP LV at 5 months and the ADA LV at 8 months
(9,733 ± 333 mg/mL); the difference was not statistically significant
(p = 0.0722). When the ADA LV was administered first, both vectors
were detected and there were no differences in the ADALV liver VCN
or in the subsequent the eGFP LV liver VCN, regardless of whether
the eGFP LV was pegylated or not (Figure 3D). Remarkably, when
the ADA LV was administered as the second vector after treatment
with either the eGFP LV or the PEG-eGFP LV, no ADA LV was de-
tected in liver.
To further test re-administration and the potential for inactivation,
we gave Ada+/ mice previously treated with an ADA LV as neo-
nates a “booster” of the same ADA LV at 5 months and with the
eGFP LV (n = 5) or PEG-eGFP LV (n = 5) at 8 months. Unexpect-
edly, three administrations of the LV over 8 months reduced
the probability of survival to 60% in both treatment arms, with
loss of mice within 30–60 min of receiving the third LV administra-
tion (Figure 3B). Those that survived the third injection were inac-
tive post injection but recovered within 1 h and survived to the
study endpoint. In the surviving mice, there were no differences82 Molecular Therapy: Methods & Clinical Development Vol. 16 Marchin anti-vector IgG concentration in mice treated with the ADA
LV at birth and at 5 months and the eGFP LV at 8 months
(17,466 ± 466 mg/mL) compared to mice treated with the ADA
LV at birth and at 5 months and the PEG-eGFP LV at 8 months
(17,133 ± 2018 mg/mL) (p = 0.6579). Likewise, there were no differ-
ences (p = 0.1052) in the mean liver VCN with the ADA LV admin-
istered at birth and 5 months, nor with the unmodified eGFP LV
(0.003 ± 0.001 ADA copies, 0.238 ± 0.208 eGFP copies) or PEG-
eGFP LV (0.063 ± 0.05 ADA copies, 0.028 ± 0.017 eGFP copies)
administered at 8 months (Figures 3C and 3D).
Dosing Schedule and Biodistribution in Rhesus Monkeys
In parallel studies, we determined the biodistribution of simian im-
munodeficiency virus (SIV)mac1A11-based LVs in rhesus monkeys
when administered intravenously at birth (study 1) or 4 months
of age (study 2) (Table 1; Table S2). Previously, we compared
the biodistribution of HIV-1 LVs and SIV LVs in rhesus
neonates and found the biodistribution to be similar despite the
well-described TRIM5a-mediated host restriction observed in
nonhuman primate HSCs to HIV-1 viral vector integration.16 We
used the species-specific SIV LVs pseudotyped with the VSV-G en-
velope in these studies. The expression cassette contained the MND
enhancer/promoter driving expression of human Ada cDNA (Fig-
ure S1)9. All rhesus monkeys had birth weights and growth trajec-
tories within the normative range (data not shown). Blood samples
were collected for complete blood counts (CBCs) and chemistry
panels, all of which were within the anticipated range for rhesus2020
Figure 2. Immunogenicity of Unmodified and PEGylated LVs in Immune-Competent Ada+/– Mice
(A) Schematic of study design. (B) Kaplan-Meier survival curves. (C) Mean (±SEM) concentration of anti-vector antibodies (mg/mL). (D) Mean (±SEM) liver VCNs.
www.moleculartherapy.orgmonkeys in this age group (data not shown). There were no adverse
events observed in any of the animals throughout the study and to
the endpoint (1 year of age).
To model biodistribution in young animals, we treated rhesus mon-
keys at birth (study 1) or at 4 months of age (study 2) in dose-
response studies. In study 1, rhesus monkeys were administered
the SIV-ADA LV at birth at one of two dose levels, 1.0  10e10
TU/kg (n = 3) or 1  10e11 TU/kg (n = 3) with tissue harvests per-
formed at 12 months of age (12 months post transfer). VCN was
dose-dependent with vector sequences detected in liver and adrenal
glands at both dose levels and in lung, heart, kidneys, omentum,
spleen, and bone marrow only at the higher dose (Figure 4A). In
study 2, rhesus monkeys were administered the LV at 4 months
of age at one of two dose levels, 3.7  10e9 TU/kg (n = 3) or
3.7  10e10 TU/kg (n = 3) with tissue harvests performed at
10 months of age (6 months post transfer). In general, the VCN
increased in liver and spleen with increased dose and vector was de-
tected in the heart, adrenal glands, muscle, lymph nodes, and bone
marrow only at the higher dose (Figure 4B). Overall, liver VCN
ranged from 0.0008 to 0.015 and was similar at higher and lowerMoleculdoses studied when comparing rhesus monkeys treated at birth or
4 months of age. Furthermore, in rhesus monkeys treated at
4 months of age, marking was less than in those treated at birth
when comparing VCN in lung, heart, and adrenal glands, whereas
it was higher in spleen, lymph nodes, and bone marrow. It is
possible the difference in marking may be due to the maturation
of the immune system (between birth and 4 months of age).
Re-administration of LV in Immune-Competent Rhesus
Monkeys
To investigate the potential for inactivation of vector upon re-
administration, we administered to rhesus monkeys the SIV LV car-
rying the non-expressed transgene, FXM10 (FX LV) or the non-ex-
pressed neomycin resistance gene (NeoNT LV) (Figure 5; Table S3).
All LVs were administered intravenously at a dose of 2.0  10e9
TU/kg (Table 1).
In study 3, rhesus monkeys #1 and #2 were treated with the FX LV at
1 month of age (Figures 5A and 5B) and rhesus monkeys #3 and #4
were treated with the NeoNT LV at 4 months of age (Figures 5C
and 5D). Rhesus monkeys #5 and #6 were treated with the FX LVar Therapy: Methods & Clinical Development Vol. 16 March 2020 83
Figure 3. Repeat Administration of Unmodified and PEGylated LVs in Immune-Competent Ada+/– Mice
(A) Schematic of study design. Dark arrows represent the first vector administered and light arrows represent the second vector administered. (B) Kaplan-Meier survival. (C)
Mean (±SEM) concentration of anti-vector antibodies (mg/mL). (D) Mean (±SEM) liver VCN of each transgene: first-administered LV transgene (gray bar) and the second-
administered LV transgene (black bar).
Molecular Therapy: Methods & Clinical Developmentat 1 month of age and the NeoNT LV at 4 months of age (Figures 5E
and 5F). Tissue harvests were performed at 7months of age (6months
post vector administration when treated at 1 month of age or
3 months post transfer when last vector administration was at
4 months of age). Liver VCN was similar in rhesus monkeys treated
with FX LV at 1 month only or with the NeoNT LV at 4 months
only. However, in animals treated with the FX LV at 1 month and
with the NeoNT LV at 4 months, there was no detectable NeoNT
LV copies in liver or in any tissue analyzed (data not shown). Anti-
vector IgG was detected within 2 to 3 months after the first exposure
to LV, with IgG concentrations in rhesus monkeys administered both
the FX LV at 1 month and NeoNT LV at 4 months similar to those
detected in monkeys treated with only a single LV. These results sug-
gest the anti-vector response after one exposure was sufficient for
complete inactivation of the second LV administered.
In study 4, we set out to determine whether a pegylated LV
would prevent the inactivation of the second-administered LV.
Rhesus monkeys were treated with the FX LV at 3 months of84 Molecular Therapy: Methods & Clinical Development Vol. 16 Marchage and with either the unmodified NeoNT LV or with the NeoNT
LV that was modified by pegylation (PEG-NeoNT LV) at 6 months
of age (Figure 6; Table S3). The NeoNT LV titer was 1.6  10e10
TU/mL and the PEG-NeoNT LV titer was 9.6  10e9 TU/mL.
The NeoNT LV had 0 ng/mL PEG molecules, while the PEG-Ne-
oNT LV had 275,000 ng/mL PEG molecules (Table S4). All LVs
were administered intravenously at a dose of 2.0  10e9 TU/kg
(Table 1).
Rhesus monkeys #7 and #8 were treated with the PEG-NeoNT LV
at 6 months of age (Figures 6A and 6B), #9 and #10 were treated
first with the FX LV at 3 months of age followed by the unmodified
NeoNT LV at 6 months of age (Figures 6C and 6D), and #11 and
#12 were first treated with the FX LV at 3 months of age followed
by the PEG-NeoNT LV at 6 months of age (Figures 6E and 6F). Tissue
harvests were performed at 10 months of age (4 months after the last
vector administration). These studies resulted in liver marking similar
to the marking observed in study 3 with the unmodified NeoNT,
suggesting that the PEG-NeoNT LV was able to transduce the liver.2020
Figure 4. Biodistribution in Rhesus Monkeys: Dose Response after LV Administration at Birth or 4 Months of Age
(A) Biodistribution of LVs after rhesus monkey newborns were treated at birth (study 1) with an intravenous injection of the SIV-ADA LV at 1.0  10e10 TU/kg (n = 3) or
1.0 10e11 TU/kg (n = 3). (B) Biodistribution of LVs after rhesus monkeys were treated at 4 months of age (study 2) with an intravenous injection of the SIV-ADA LV at 3.7
10e9 TU/kg (n = 3) or 3.7  10e11 TU/kg (n = 3). Data are plotted as 10th–90th percentile whisker plots with 50th percentile denoted (median).
www.moleculartherapy.orgIn the rhesus monkeys treated with both vectors, only the first
vector administered (FX LV) was detected, whereas none of the
monkeys had evidence of marking with the subsequent administra-
tion of the NeoNT LV or the PEG-NeoNT LV. Further, there was
no difference in the anti-vector response after injection of the first
LV. These results suggest that pegylation of LV was unable to prevent
inactivation of the second LV administered and that the response to
vector administration at first exposure was sufficient to inactivate the
second injection.
Further Characterization of the Anti-Vector Response in Mouse
and Rhesus Monkey Samples
The specificity of the anti-vector response was further characterized
in terms of cross-reactivity to different antigen capture LVs. LVs eval-
uated in the ELISA had different transgenes, vector backbones, and
pseudotypes. Plasma samples from treated mice and monkeys tested
included LVs carrying expressed transgenes (ADA, eGFP) and non-
expressed transgenes (FX and NeoNT). In all cases, the magnitudeMoleculof the antibody response against LVs with expressed and non-ex-
pressed transgenes was not significantly different, nor were the re-
sponses specific to the LV and transgene to which the animal was
exposed. Plasma from treated rhesus monkeys was equivalently
reactive to SIV LV and HIV LV capture antigens, even though treated
animals were only exposed to SIV LV (data not shown). Similarly,
plasma from LV-treated mice was equivalently reactive to SIV LV
and HIV LV capture antigens, although mice were only exposed
to HIV LV (data not shown), suggesting that the response is not spe-
cific for capsid or gag proteins p27 or p24, respectively. Comparing
plasma samples from mice treated with LV pseudotyped with VSV-
G were equivalently reactive to LV pseudotyped with murine ampho-
tropic leukemia virus envelope, murine ecotropic Moloney leukemia
virus envelope, Gibbon-Ape virus envelope, or RD114 endogenous
feline virus envelope. In all mouse plasma tested, the results were
similar, indicating the response was not VSV-G specific (data not
shown). Taken together, these data suggest that the response is not
LV specific.ar Therapy: Methods & Clinical Development Vol. 16 March 2020 85
Figure 5. Repeat Administration of VSV-
Pseudotyped LVs with Non-expressed Transgenes
in Immune-Competent Rhesus Monkeys
Liver VCN (A, C, and E) and the concentration of anti-
vector antibody detected in plasma (mg/mL) at 0 (pre), 3,
and 6 months after the first vector treatment (B, D, and F)
are shown for each pair of treated monkeys. (A and B)
Rhesus monkeys #1 and #2 were administered the FX LV
at 1 month of age. (C and D) Rhesus monkeys #3 and #4
were administered the NeoNT LV at 4 months of age. (E
and F) Rhesus monkeys #5 and #6 were administered
both the FX LV at 1 month of age and the NeoNT LV at
4 months of age.
Molecular Therapy: Methods & Clinical DevelopmentAdditional ELISAs were performed using lysates from HEK293T
cells as capture antigens. The packaging cell lines were transfected
with the VSV-G expression plasmid alone, with the packaging
plasmid (gag-pol) alone, or with both the VSV-G plasmid and the
gag-pol plasmid. Plasma samples from several test conditions were
pooled as the supply of murine plasma samples was limited. There
was no response to the capture antigen from lysates of 293T cells
transfected with the packaging plasmid alone, but the concentration
of antibody increased 10-fold above background with lysates of
293T cells transfected with the VSV-G plasmid alone or together
with the packaging plasmid. However, all responses were 1,000- to
100,000-fold lower than the response to the concentrated viral vector
preparation depending on the test condition (Table S5; Figure S3).
DISCUSSION
The initial focus of our studieswith systemic LVadministration centered
on the specific disease model of ADA-deficient SCID and correction of
the phenotype associatedwith knockout of theAda gene. Further studies
were performed to understand issues surrounding scalability, species-
specific vector systems, and the best approach for modeling
biodistribution after systemic LV administration.6,16 In the studies pre-
sented herein, we investigated age, dose, dosing schedules, re-adminis-
tration, and the potential for viral inactivation after repeat administra-
tion in the ADA-deficient mouse model and in healthy young rhesus86 Molecular Therapy: Methods & Clinical Development Vol. 16 March 2020monkeys. Although the ADA-deficient mouse
model was included to address specific questions
aboutADAdeficiency and the potential of ectopic
ADA expression supplied in vivo by LV-trans-
duced tissues, the results presented have implica-
tions for other diseases in which LV-mediated
gene transfer in vivo has shown promise.
To examine how age at treatment affects bio-
distribution, Ada/ mice were treated as Neo-
nates or as Adults previously maintained on
ERT using PEG-ADA (as Ada/ mice live no
longer than 3 weeks without an exogenous
source of ADA enzyme). Ada/ Neonates
were treated with a LV dose previously found
to be necessary for survival. When treating theAda/ Adult mice, however, we were unable to deliver the concen-
trated LV dose within a single 100 mL injection volume, and thus the
mice were treated with a reduced dose. Survival was high in all
Ada/ mice treated with ADA LV and 1 month of ERT, which was
necessary to avoid loss from inadequate ADA expression. The bio-
distribution was most likely affected by dose because overall marking
in mice treated as adults was reduced. The reduction in VCN in liver,
lung, thymus, and brain, however, far exceeded the difference in dose.
In parallel studies, rhesus monkeys were treated at birth (study 1) or
at 4 months of age (study 2) with one or two different doses and
analyzed at approximately 1 year of age (12 months or 8 months
post transfer, respectively). In each study, rhesus monkeys were
treated with the maximum dose possible within a 1 mL injection vol-
ume or a dose one-tenth lower. LV marking in liver was dose-depen-
dent with 10-fold differences in dose level and did not differ in rhesus
monkeys treated at 4 months of age with one-third the dose admin-
istered to rhesus at birth. Furthermore, those animals injected at
4 months of age versus on the day of birth had detectable marking
in spleen, lymph nodes, and bone marrow. Taken together, these
results suggest it may be possible to achieve a similar biodistribution
by treating infants at 4 months of age compared to birth with less
vector and may represent an important step toward future clinical
development of this treatment modality based on age.
Figure 6. Re-Administration with a Pegylated LV
Compared to an Unmodified LV in Immune
Competent Rhesus Monkeys
Liver VCN (A, C, and E) and the concentration of anti-
vector antibody detected in plasma (mg/mL) at 0 (pre), 3,
and 6 months after the first vector treatment (B, D, and F)
are shown for each pair of treated monkeys. (A and B)
Rhesus monkeys #7 and #8 were administered the PEG-
NeoNT LV at 6months of age. (C and D) Rhesusmonkeys
#9 and #10 were administered the FX LV at 3 months of
age and the unmodified NeoNT LV at 6 months of age. (E
and F) Rhesus monkeys #11 and #12 were administered
the FX LV at 3 months of age and the PEG NeoNT LV at
6 months of age.
www.moleculartherapy.orgLiver-directed therapy by systemic administration of LVs to treat
disease states caused by monogenic mutations, such as ADA-defi-
ciency, mucopolysaccharidoses (MPS: I, IIIa, VII), or hemophilia
(Factor VIII or IX) may require re-administration of vector at
some point after the initial treatment, because there is currently
no evidence that cells with self-renewing capacity are transduced.
Most of the adaptive immune responses reported after systemic
LV administration were directed toward the transgene product ex-
pressed in vivo.21,22 For example, one study found transgene-specific
cytotoxic and humoral responses to Factor IX expressed in liver2
and another described cytotoxic T cell responses specific to lucif-
erase expressed in the lungs,23 which resulted in reduced transgene
expression. In our studies, we analyzed an anti-vector adaptive im-
mune response and the potential for inactivation of subsequent
LV administration in the ADA-deficient mouse model and in young
rhesus monkeys. Furthermore, in the monkey studies, the use of
non-expressed transgenes limited the potential for transgene-spe-
cific responses.
In single-exposure studies with unmodified ADA LV, neither im-
mune-deficient Ada/ mice nor immune competent Ada+/ mice
treated as neonates had no or little anti-vector IgG response. This
finding is more likely related to the tolerizing effect of neonatal
exposure to vector, as has been demonstrated in studies with ad-Molecular Therapy: Methods &eno-associated viral vectors (AAV).24–26 In
Ada/ mice treated at 4 months of age (after
4 months of ERT), the concentration of anti-
vector antibody increased 15,000- to 20,000-
fold, a magnitude of increase not observed in
immune-competent Ada+/ mice treated as
adults. The extent of the response suggests a
dysregulated response in Ada/ mice treated
as adults after treatment with PEG-ADA
ERT. Indeed, dysregulation of the immune sys-
tem after immune reconstitution with PEG-
ADA ERT has been reported in Ada/ mice
and ADA-deficient patients.27,28 Furthermore,
responses in those Ada/ mice treated with
LV twice within 3 days had higher levels of
IgG and diminished marking in liver andspleen. Others have shown that systemic administration of LV
can also activate the innate immune response, resulting in the acti-
vation of Toll-like receptor (TLR)-dependent and -independent
pathways29 and higher numbers of transduced macrophages than
transduced hepatocytes.30 The double administration of LVs within
3 days may have enhanced the transduction of macrophages, ulti-
mately resulting in a heightened adaptive response.
We also investigated the potential for pegylation of VSV-G LV to
reduce immunogenicity. We hypothesized that a PEG-modified LV
would prevent an adaptive immune response, evade pre-existing re-
sponses from an initial administration, and preserve transduced
liver cells. Pegylation of viral vectors was demonstrated to increase
stability and reduce immunogenicity in a variety of viral vector sys-
tems including LVs.19 Systemic administration of PEG-modified
VSV LV resulted in a longer half-life and increased marking in
spleen, liver, and bone marrow of mice compared to unmodified
VSV LV. To PEG-modify the LV, we developed a novel technique
for conjugating PEG molecules to VSV during the concentration
phase of vector production without a significant reduction in titer.
Additionally, free unconjugated PEG molecules were successfully
removed during concentration at the buffer exchange step of tandem
flow filtration (TFF).20 To compare the effects of pegylation, we split
vector batches into two fractions, with one-half pegylated and theClinical Development Vol. 16 March 2020 87
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competent Ada+/ mice and healthy young rhesus monkeys.
The use of PEG-modified LV was safe as there were no adverse
events in immune-competent Ada+/ mice when treated with
PEG-modified LV as the sole treatment or as part of a dual treat-
ment. Ada+/ mice treated as adults with a single administration
of the ADA LV, the unmodified eGFP LV, or PEG-eGFP LV, also
showed no differences in either the anti-vector IgG concentration
or in liver VCN. However, when Ada+/ mice were treated with
the PEG-eGFP LV once at 5 months and again at 8 months, the
anti-vector response was significantly higher compared to those
mice treated once with eGFP LV or PEG-eGFP, suggesting no pro-
tection with pegylated VSV LV.
Further, in re-administration studies with unmodified and PEG-
modified LV over several months, both mice treated as adults and
newborn or infant rhesus monkeys completely inactivated the sec-
ond-administered LV resulting in no detectable marking. When
mice were treated with either the unmodified eGFP LV or the PEG-
modified eGFP LV at 5months, followed by the ADA LV at 8months,
the ADA LV was not detected in the liver. When rhesus monkeys
were treated with the non-expressed FX LV at 1 or 3 months of age
(study 4) and then with either the unmodified or pegylated non-ex-
pressed NeoNT LV, the NeoNT LV was not detected in the liver.
Because this finding was similar when comparing LVs carrying ex-
pressed transgenes or non-expressed transgenes, it is not likely that
the transgene product was the neoantigen. In addition, these results
suggest that the PEG-modified LV could not prevent inactivation.
However, the concentration of anti-vector antibody detected when
the first vector was PEG-modified was more than 10-fold lower
than when the first vector was unmodified. These findings also sug-
gest that the first exposure is sufficiently strong to elicit an adaptive
immune response that may be attenuated with age. These findings
are unlike those found with AAV serotype 8; when treatment was de-
layed from a newborn to 1 month of age, the antibody response to
capsid was decreased.31
In an additional study, when mice were treated with LV three times,
once as a neonate, once at 5 months, and again at 8 months of age,
there was acute toxicity and 40% of the mice succumbed within 1 h
of the third treatment. The same number of animals was lost when
the third LV was unmodified LV or PEG-modified LV. Despite the
acute toxicity, in the surviving mice the inactivation of the last LV
was not complete, with the third vector detectable regardless of
whether it was PEGylated or not. Indeed, in all Ada+/ mice treated
as neonates, the unmodified ADA LV resulted in detection of subse-
quent vectors, suggesting neonatal administration may have induced
tolerance and the potential for inactivation but was insufficient to
prevent toxicity when the third treatment was with unmodified or
pegylated LV. Furthermore, these results are in line with findings in
rhesus monkeys where no adverse events were observed and suggest
that PEG-modified vectors did not prevent inactivation or acute
toxicity.88 Molecular Therapy: Methods & Clinical Development Vol. 16 MarchTo characterize the anti-vector response, we performed cross-reac-
tivity studies using different capture antigens (SIV LV versus HIV
LV, LV pseudotyped with VSV-G versus ecotropic envelope versus
amphotropic envelope, VSV-gamma retroviral vector (gRV) versus
VSV-LV) with murine and rhesus monkey samples. The results of
these comparisons demonstrated that the response was not transgene
specific, vector backbone specific, capsid specific, or envelope specific.
Furthermore, studies conducted using lysates from transfected
HEK293T cells as capture antigen indicated that gag pol proteins or
VSV-G were not responsible for the entire response observed because
the overall responses were over 1,000-fold lower than those seen with
packaged LV.
We hypothesized that the adaptive anti-vector response is polyclonal
in nature, with antibodies generated to a variety of components in
common with the various HIV-1 and SIV LV used in these studies,
including other viral proteins and producer cell DNA and proteins.
There are limited re-administration studies to support this hypothe-
sis, but one study demonstrated that sera from rats injected with
a VSV-G-eGFP LV into the striatum followed by a subcutaneous
injection of the same LV or a different VSV-G-Factor IX LV resulted
in antibodies to capsid protein, matrix protein, and VSV-G proteins
as detected by immunoblot and that capsid-specific antibodies
blocked subsequent LV administration.32
Other studies suggest that more than viral proteins can act as anti-
gens. Proteomics analysis of LVs revealed an array of human pack-
aging cell proteins, including nuclear proteins, elongation factors,
chaperone proteins, and heat shock proteins, co-packaged into the
virion and released upon entry into the cell.33 It is not clear whether
these proteins would elicit a response in humans, but they may be
antigenic when administered to mice and nonhuman primates. In
another study, it was demonstrated that VSV-G-pseudotyped LV
produced by transient transfection contain tubulovesicular structures
(TVSs) that are similar to micro-vesicles found in viral stocks of HIV-
1, which were determined to contain producer cell DNA and proteins
and residual plasmid DNA and proteins present in the cell culture
medium.34 These authors found that plasmid DNA associated with
TVSs, but not VSV-G, was shown to elicit a Toll-like receptor 9
(TLR 9)-dependent response and was a potent adjuvant when co-
administered with ovalbumin to produce T and B cell adaptive re-
sponses, concluding that TVS-associated plasmid may result in a
similar finding with other viral proteins.
It is unclear whether systemic delivery of LV could be used as an
additional treatment option for many ADA-deficient SCID patients,
given the success with ex vivo gene therapy using gamma-retroviral
or LV to genetically modified stem cells. Nevertheless, these studies
are important for highlighting the complexities involved in devel-
oping novel therapeutics for SCID and other disorders. These studies
reveal several factors that may be important to consider when trans-
lating liver-directed gene transfer with systemic administration
of LVs for any indication. Specifically, we have demonstrated that
treatment age, immune status, and frequency of administration2020
www.moleculartherapy.orgcan impact outcomes. Lastly, additional safeguards should be consid-
ered, such as requiring that LV production occur in human cells to
reduce immunogenicity and the development of specific screening
methods to track immunological responses after systemic administra-
tion of LV, particularly before considering re-administration.
Screening is routinely performed in nonhuman primate studies
conducted with AAV to avoid using animals with pre-existing
neutralizing antibodies.31 Further strategies may need to be adapted
from the AAV field, such as pre-treatment with immunosuppressive
agents, particularly in immune-competent individuals.35
MATERIALS AND METHODS
Vectors
Vector maps are depicted in Figure S1. The HIV-1-based, self-inacti-
vating (SIN) LV CSO-rc-MNDU3-ADA (MND-ADA LV), CCL-
MNDU3-eGFP (eGFP LV), and the SIV-based LV CL20c-SM-
hADA (SIV-ADA LV), CL20c-SM-NeoNT (NeoNT LV), and
CL20c-SM-FXM10 (FX LV) were as previously described.9,16 The
EFS-ADA LV which contains the shortened version of the elongation
factor 1 alpha gene promoter (EFS) was also described previously.36
The EFS-ADA LV was modified to include the A2 ubiquitous chro-
matin opening element (UCOE, 1.5 fragment), upstream of the EFS
promoter (UCOE-EFS-ADA LV).37 The HIV-based and SIV-based
vectors were packaged and titer was determined as previously re-
ported.16,20 Tissue VCN and ADA activity for each vector are shown
in Figure S4.
Pegylation of Lentiviral Vectors
A 2-liter preparation of LV was prepared by transient transfection
in 10% X-Vivo15 (Lonza, Allendale, NJ, USA) and partially
concentrated (70-fold) with the TFF Diafiltration System (Spec-
trum Laboratories, Rancho Dominguez, CA, USA).20 The partial
concentrate was diluted in Dulbecco’s phosphate-buffered saline
(DPBS) (Mediatech, Manassas, VA, USA) to a volume of 30 mL
and was split into two fractions. The protein concentration of
each fraction was determined (Pierce BCA Protein Assay, Pierce,
Waltham, MA, USA). Succinimidyl-succinate activated monome-
thoxypoly (ethylene) glycol, mw-5000 (SSPEG, Sigma-Aldrich, St.
Louis, MO, USA), was prepared as a 10 solution of 100 mg/mL
in DPBS. Using the volume of the fraction to be pegylated and
the total amount (mg) of vector protein pegylated to determine
the appropriate volume of 10 SSPEG to add, 10 mg of SSPEG
was used per mg of vector protein. Succinimidyl-succinate activated
monomethoxypoly (ethylene) glycol, mw-5000 (SSPEG, Sigma-Al-
drich, St. Louis, MO, USA), was prepared as a 10 solution of
100 mg/mL in DPBS. The 10 SSPEG was diluted with sufficient
DPBS to match the volume of the vector to be pegylated and
was added to the vector in a 1:1 ratio. To mock-pegylate the second
fraction of vector, we diluted the vector 1:1 with DPBS. Both frac-
tions were incubated for 1 h at 25C with gentle agitation. To bind
the free SSPEG molecules, we added L-lysine (Sigma, St. Louis,
MO, USA) at 10 mg per mg of SSPEG added. Each fraction was re-
turned to TFF to further concentrate the vector another 40-fold,
as well as remove the excess lysine, free SSPEG, and reaction by-Moleculproducts. The PEG-modified LV and unmodifiedLV were stored
as injectable aliquots at %80C. Titer was determined on HT-
29 cells (ATCC HTB38) and the number of viral particles deter-
mined by p24 ELISA (Perkin Elmer, Waltham, MA, USA).18
Anti-PEG Direct Competitive ELISA
The concentration of PEG molecules was determined using a
direct-competitive, high-sensitivity anti-PEG ELISA kit (Life Diag-
nostics, West Chester, PA, USA). Microtiter plates were pre-coated
with PEG-BSA. The LV preparation was diluted 1:1,000 and
applied to the microtiter plate. Horseradish peroxidase (HRP)-con-
jugated anti-mouse monoclonal antibody specific to the PEG back-
bone (50 mL) was added to the plate and incubated for 1 h with
shaking. Conjugated and free PEG compete for the antibody
such that the amount of antibody remaining was captured by
the bound PEG-BSA. After washing the wells with PBS, 0.1 mL
TMB (3,30,5,50-tetramethylbenzidine) was added to the wells
and the plate was incubated for 20 min before stopping the reac-
tion with 0.100 mL of 1N HCl. Absorbance was read at 450 nm.
The amount of PEG in the sample was inversely correlated to
the absorbance. The optical density (OD) of the samples was
compared to a standard curve of diluted PEG-BSA to determine
concentration of PEG (ng/mL) present in the vector preparations.
Mice
Mice were housed in accordance with the requirements of the Animal
Welfare Act. All protocols adhere to NIH guidelines and were
approved by the Animal Research Committee, Division of Laboratory
Animal Medicine, at the University of California, Los Angeles
(UCLA). The ADA-deficient mouse model was generated and
rescued with a two-stage genetic engineering strategy previously
described and characterized.38 Due to the accumulation of adenosine
and deoxyadenosine, the mice exhibit multi-system abnormalities,
including the SCID phenotype prior to loss at postnatal day 19–20
(3 weeks) from pulmonary insufficiency.39 Mouse husbandry, gen-
otyping procedures, and intravenous administration of LV were per-
formed as previously described.9 Ada/ mice were maintained via
weekly intramuscular injection of 50 U/kg body weight of pegylated
bovine ADA (ADA-GEN; a kind gift from Leadiant Pharmaceuticals,
Gaithersburg, MD, USA). All animals were housed in micro-insulator
cages in a pathogen-free colony and all procedures were conducted in
laminar flow hoods.
Mouse Studies
For systemic administration of LV into mice, vector aliquots
were thawed quickly and diluted, if necessary, to a 50 or 100 mL
injection volume in 0.9% saline (injection, USP; APP, Schaumburg,
IL, USA) as described previously.9 Entire litters of Ada/ and
Ada+/ neonates were injected with 50 mL of vector on postnatal
day 1–3 via the superficial temporal vein using a 30G needle attached
to a 1 mL syringe without sedation. Neonates received 2.5–5 10e10
TU/kg of an ADA LV (either MND-ADA LV, EFS-ADA LV, or
UCOE-EFS-ADA LV). Approximately half of the litters treated
were also given supplemental ERT for 30 days after LV injection.ar Therapy: Methods & Clinical Development Vol. 16 March 2020 89
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via the tail vein with a 27G needle attached to a 1 mL syringe without
sedation. Adult mice received 1–3.0  10e10 TU/kg of one of
the ADA LV indicated above, and all Ada/ adult mice continued
to receive ERT for 1 month. Only Ada+/ adult mice received 1.5 
10e10 TU/kg of PEG-eGFP LV or EGFP LV, and none received
supplemental ERT (Table 1). Mice were analyzed at 4, 8, or
11 months after treatment for tissue VCN, immunophenotyping,
and immune responses.
Rhesus Monkeys
All animal procedures conformed to the requirements of the
Animal Welfare Act and protocols were approved prior to imple-
mentation by the Institutional Animal Care and Use Committee
(IACUC) at the University of California, Davis. Normally cycling,
adult female rhesus monkeys (Macaca mulatta) (N = 24) with a
history of prior pregnancy were bred and identified as pregnant
using established methods.40 Activities related to animal care
were performed according to California National Primate Research
Center standard operating procedures. Newborns were delivered
by cesarean section at term according to established protocols.40
At birth, umbilical cord blood was collected.41 Infants were raised
in a dedicated nursery for postnatal studies with daily monitoring
of physical signs and food intake. Weights were also monitored on
a routine basis following established nursery protocols.
Monkey Study 1
Rhesus monkeys (Tables 1 and S1) were administered an intravenous
injection of the SIV-ADA LV in 1 mL volume, via a peripheral
vessel at birth (n = 6; 2 females and 1 male [1  10e10 TU/kg], and
3 females [1  10e11 TU/kg]; 500 g at birth). Blood samples
(1–3 mL) were collected from a peripheral vessel prior to vector
administration, then at 1, 3, 7, 14, and 30 days, and then approxi-
mately every other month from 2 through 12 months of age (CBCs,
chemistry panels, qPCR). Tissue harvests were performed at
12 months of age (12 months post-administration; body weight range
at tissue harvest 1.8 kg to 2.5 kg).
Monkey Study 2
Rhesus monkeys (Tables 1 and S2) were administered an intrave-
nous injection of the SIV-ADA LV in 1 mL volume via a periph-
eral vessel at 4 months of age (n = 6; 2 females and 1 male [3.6 
10e9 TU/kg] and 2 females and 1 male [3.6  10e10 TU/
kg]; 1 kg). Blood samples (1–3 mL) were collected at 0, 1, 3,
7, 14, and 30 days, then approximately monthly from 2 through
10 months postnatal age (CBCs, chemistry panels, qPCR). Tissue
harvests were performed at approximately 10 months of age
(6 months post-administration; body weight range at tissue harvest
1.8 kg to 2.6 kg).
Monkey Study 3
Rhesus monkeys (n = 6, 2 per group; 3 females, 3 males; Table S2)
were administered SIV LV carrying non-expressed transgenes
(Table 1). They were treated with either the FX LV at 1 month of90 Molecular Therapy: Methods & Clinical Development Vol. 16 Marchage or the NeoNT LV at 4 months of age only or with both the
FX LV at 1 month of age and the NeoNT LV at 4 months of age.
Blood samples (1–3 mL) were collected at 0, 1, 3, 7, 14, and
30 days and then approximately monthly from 2 through 7 months
of age (CBCs, chemistry panels, anti-vector ELISA, and qPCR). Tis-
sue harvests were performed at 7 months of age (6 months post-vec-
tor administration when treated at 1 month of age or 3 months
post-treatment when the last LV administration was at 4 months;
body weight range at tissue harvest 1.7 kg to 2.1 kg).
Monkey Study 4
Rhesus monkeys (n = 6, 2 per group; 3 females, 3 males; Table S2)
were administered SIV LV carrying non-expressed transgenes (Table
1). Monkeys were either treated with the FX LV at 3 months of age
only, or with the FX LV at 3 months followed by the NeoNT LV at
6 months of age or the PEG NeoNT LV at 6 months of age. Blood
samples (1–3 mL) were collected at 0, 1, 3, 7, 14, and 30 days,
then approximately monthly post-vector administration (CBCs,
chemistry panels, anti-vector ELISA, and qPCR). Tissue harvests
were performed at 10 months of age (4 months after the last vector
administration; body weight range at tissue harvest 1.8 kg to 2.9 kg).
Post-Study Tissue Analysis
All animals were sedated with ketamine (10 mg/kg) then euthanized
with an overdose of pentobarbital for tissue harvest according to es-
tablished protocols.41 Blood samples were collected, total body
weights and measures were assessed, all organs were removed, and
selected tissues weighed (e.g., brain, thymus, spleen, liver, adrenal
glands, kidneys, and gonads). Tissues collected included the brain
(cerebrum and cerebellum), lung (all lobes), trachea, esophagus, heart
(right and left ventricle), aorta, pericardium, thymus, spleen, liver (all
lobes), lymph nodes (right and left axillary and inguinal, tracheobron-
chial, and mesenteric), pancreas, right and left adrenal glands, right
and left kidneys, reproductive tract (right and left gonads and uterus
or right and left seminal vesicles and prostate), gastrointestinal tract
(stomach, duodenum, jejunum, ileum, and colon), right and left
muscular component of the diaphragm, omentum, right and left
body wall (peritoneum), skin, muscle, and bone marrow. No abnor-
malities were detected during the in-life phase or at tissue harvest.
All tissues collected for qPCR were placed in tubes and immediately
frozen in liquid nitrogen and stored at%80C until assay.
VCN Quantification
VCNwas determined by qPCR on genomic DNA extracted from cells
and tissues. Primers and probes were previously described.16 Quanti-
tative real-time PCR analysis was carried out in 96-well optical
plates using the 7900 ABI Sequence Detection System (Applied Bio-
systems, Foster City, CA, USA) and TaqMan Universal PCR Master
Mix (Applied Biosystems, Foster City, CA, USA) according to the
manufacturer’s protocols and as previously described.15 PCRs were
run in triplicate in separate wells with 400 nM of each primer and
100 nM probe in a 25 mL reaction volume. The PCR protocol con-
sisted of 1 cycle of 2 min at 50C and 15 min at 95C, followed by
40 cycles of 15 s at 95C and 60 s at 60C.2020
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The concentration of anti-vector IgG antibodies in plasma or sera
was determined by ELISA. Concentrated VSV-G-pseudotyped LV
(>1  10e8 TU/mL) was used as the capture antigen, and the
entire procedure was performed to BSL2 standards in a biosafety
cabinet with all excess vector, antibody, and washes aspirated into
a 10% bleach solution. Nunc PVC 96 flat-well plates were coated
(50 mL/well) with LV diluted 1:1,000 (20 mg/mL) in 100 mM
bicarbonate/carbonate binding buffer (3.03 g Na2CO3 and 6.0 g
NaHCO3 in 1,000 mL distilled water, pH 9.6) and incubated
overnight at 4C. The plates were washed three times with
wash buffer (DPBS with 0.05% Tween-20; Sigma-Aldrich, St.
Louis, MO, USA), followed by blocking with blocking buffer
(DPBS with 1% fetal bovine serum [FBS]) for 1 h. A murine
monoclonal anti-vector antibody at 200 mg/mL (sc-365019, Santa
Cruz Biotechnology, Santa Cruz, CA, USA) was serially diluted
12 1:10 (20 mg/mL) in blocking buffer for a total of 100 mL/
well. Plasma samples were diluted 1:20 in blocking buffer and
serially diluted 12 1:10. The plate was incubated with gentle
agitation at room temperature for 2 h and then washed 3
with wash buffer. Secondary goat anti-mouse IgG-HRP antibodies
(sc-2005, Santa Cruz Biotechnology, Santa Cruz, CA, USA) were
used to detect bound anti-vector mouse IgG, and goat anti-mon-
key IgG-HRP antibodies (sc-2458, Santa Cruz Biotechnology,
Santa Cruz, CA, USA) were used to detect bound anti-vector
monkey IgG. The secondary antibodies were diluted 1:2,000 in
blocking buffer and 50 mL was added to each well. After 1 h in-
cubation with gentle agitation, the wells were washed 3 with
wash buffer. After aspiration of the last wash, 50 mL of HRP sub-
strate (3,30,5,50-tetramethylbenzidine) liquid soluble HRP/chro-
matin/peroxidase substrate system (Moss, Pasadena, MD, USA)
was added to each well. After a 5-min incubation at room tem-
perature, 50 mL of HCl (0.1N) stop solution was added to each
well. The absorbance (OD) was read at 450 nm and background
subtracted out. The OD of the murine anti-vector monoclonal
antibody dilutions were used to construct a standard curve using
second-order log regression from which the experimental anti-
vector IgG concentrations were determined.
Immunophenotypic Analysis
The lymphocyte immunophenotype was determined by flow cytom-
etry, as previously described.17 Briefly, cell suspensions were made
from the large lobe of the mouse thymus and apical half of the
mouse spleen using mechanical pressure through a 70 mm screen.
Red blood cells were lysed, and the remaining cells were counted
and stained. Thymocytes were double stained with anti-CD4 and
anti-CD8 antibodies to determine the single positive and double
positive/negative populations. Splenocytes were stained with anti-
CD45+, anti-CD3+, and anti-CD4+ or anti-CD3, anti-CD8, and
anti-CD19. Gating on splenocyte subpopulations was as follows:
CD45+ followed by CD3+ or CD19+ or CD3+ followed by CD4+
or CD8+. Absolute cell counts were normalized mathematically by
multiplying the proportion of positive cells by the total cell count
in the organ.MoleculStatistical Analysis
Descriptive statistics such as number of observations, mean, and
SEMwere reported and presented in figures for quantitative measure-
ments. For survival outcome, Kaplan-Meier method42 and log-
rank test43 were used to summarize and compare the survival experi-
ence of mice across different groups. For quantitative outcome mea-
surements, group-wise difference was assessed by nonparametric
Wilcoxon rank sum test. The Dwass, Steel, Critchlow-Fligner
Method44 was used for p value adjustment due to multiple compari-
sons. The normality assumption was assessed before statistical
testing. For all statistical investigations, tests for significance were
two-tailed unless otherwise specified. A p value less than the 0.05
significance level was considered statistically significant. All statistical
analyses were carried out using SAS version 9.3.45SUPPLEMENTAL INFORMATION
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